乳腺癌病人血清HER-2/neu检测及其临床意义

Detection of Serum HER-2/neu and Its Significance in Breast Cancer Patients

【目的】本研究分析晚期乳腺癌患者血清HER-2/neu的水平与预后的关系,并探讨其临床意义。【方法】酶联免疫法(ELISA)检测94例晚期乳腺癌患者血清HER-2/neu的浓度,分析血清与组织中HER-2/neu表达的相关性,并分析其与患者预后的关系。【结果】94例晚期乳腺癌患者就诊时的血清HER-2/neu浓度为0.34～275.25μg/L(平均浓度为23.69μg/L)。血清HER-2/neu浓度的高低与化疗的有效性、疾病进展时间的长短无关。晚期乳腺癌患者的血清HER-2/neu浓度与肿瘤组织中HER-2/neu表达强阳性是一致的。【结论】血清HER-2/neu尚不能确立为独立的预后指标,需要更多的病例进行分析。

[Objective] This study was to analyze the relationship between the serum HER-2/neu protein levels and prognosis in advanced breast cancer patients. [Methods] The serum HER-2/neu protein levels of 94 advanced breast cancer patients were detected using ELISA method. The relationship between the protein level and patient prognosis were analyzed retrospectively. Besides, the consistency of expression in serum and tissue was also analyzed. [Results] The concentrations of serum HER-2/neu were 0.34 μg/L to 275.25 μg/L （mean 23.69 μg/L）. HERe was no correlation between serum HER-2/neu levels and time to progress （TTP）. In addition, the level of serum HER-2/neu was concordance with strong expression of HER-2/neu in tumor tissue in advanced breast cancer. [Conclusion]The clinical utility of serum HER-2/neu as a prognostic indicator has not yet been established and needs more cases to evaluate.